Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis

INTRODUCTION: Ibrutinib is an oral covalent inhibitor of Bruton's tyrosine kinase approved for the treatment of patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma and Waldenstrӧm’s macroglobulinemia. Ibrutinib has an increased risk of atrial fibrillation but the mechanism is...

Descripción completa

Detalles Bibliográficos
Autores principales: Caldeira, Daniel, Alves, Daniela, Costa, João, Ferreira, Joaquim J., Pinto, Fausto J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382095/
https://www.ncbi.nlm.nih.gov/pubmed/30785921
http://dx.doi.org/10.1371/journal.pone.0211228

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382095/
https://www.ncbi.nlm.nih.gov/pubmed/30785921
http://dx.doi.org/10.1371/journal.pone.0211228

Ejemplares similares